Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07420881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Start4All - Start Taking Action for TB Diagnosis (DARE-TB)

Study acronym: S4A-DARE-TB
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
DARE-TB has been designed to address critical evidence gaps on the diagnostic performance and operational value of near point-of-care (NPOC) nucleic acid amplification tests (NAATs) within community-based case finding (CBCF) strategies. Although World Health Organization (WHO) recommends wider access to molecular testing, its use remains concentrated in facility-based settings well short of the global targets and largely dependent on sputum production. This creates a substantial diagnostic gap for people reached through community screening who either cannot provide sputum or whose sputum specimens cannot be tested on a NAAT at a facility, particularly for marginalized, hard-to-reach populations with poor access to healthcare.
Trial Details
NCT Number NCT07420881
Lead Sponsor Liverpool School of Tropical Medicine
Collaborators: Centre for Control of Chronic Disease (CCCD),icddr,b, Comité National d'Ethique pour la Recherche en Santé Humaine, National Health Research Ethics Committee Nigeria
Conditions
(from sponsor)
TB - Tuberculosis
Related terms Latent Tuberculosis
Enrollment 60,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov